Increasing the intensity of illumination degrades the efficacy of regular CXL, but it doesn’t seem to with PACK-CXL. Why?
Mark Hillen |
Currently, corneal cross-linking (CXL) with riboflavin and UV-A light is used to perform two key roles. The first is strengthening the cornea, which helps to slow or halt corneal ectatic disorders. The second is the treatment of infectious keratitis, in a process called PACK-CXL (photoactivated chromophore for keratitis–CXL). But both applications use the same illumination protocol that was originally designed for the first application (1): 3 mW/cm² total energy UV-A illumination for 30 minutes.
Read the full article now
Log in or register to read this article in full and gain access to The Ophthalmologist’s entire content archive. It’s FREE and always will be!
Or register now - it’s free and always will be!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Ophthalmologist magazine
Or Login via Social Media
By clicking on any of the above social media links, you are agreeing to our Privacy Notice.